35 related articles for article (PubMed ID: 2119793)
1. Descriptive analysis and prognostic factors in cats with myeloma-related disorders: A multicenter retrospective study of 50 cases.
Lecot L; Desmas-Bazelle I; Benjamin S; De Fornel P; Ponce F; Kornya M; Desquilbet L; Beaudu-Lange C; Ibisch C; Sayag D; Benchekroun G; Béguin J
J Vet Intern Med; 2024; 38(3):1693-1705. PubMed ID: 38517293
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
Cerchione C; Usmani SZ; Stewart AK; Kaiser M; Rasche L; Kortüm M; Mateos MV; Spencer A; Sonneveld P; Anderson KC
Front Oncol; 2022; 12():820768. PubMed ID: 35211412
[TBL] [Abstract][Full Text] [Related]
3. Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Abramson HN
Oncotarget; 2016 Dec; 7(49):81926-81968. PubMed ID: 27655636
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Suspected Monoclonal Gammopathies: Experience in a Tertiary Care Hospital.
Chopra GS; Gupta PK; Mishra DK
Med J Armed Forces India; 2006 Apr; 62(2):134-7. PubMed ID: 27407880
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment in Multiple Myeloma.
Chen JH; Hsu SN; Huang TC; Wu YY; Lin C; Chang PY; Chen YC; Ho CL
PLoS One; 2015; 10(6):e0128905. PubMed ID: 26053837
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.
Yang J; Yi Q
Am J Blood Res; 2011 Jun; 1(1):22-33. PubMed ID: 22065141
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma.
Yun JP; Suh C; Lee E; Chang JW; Yang WS; Park JS; Park SK
J Korean Med Sci; 2006 Aug; 21(4):639-44. PubMed ID: 16891806
[TBL] [Abstract][Full Text] [Related]
8. Serum beta 2-microglobulin in acute pancreatitis.
Mora A; Pérez-Mateo M; Viedma JA; Sánchez-Payá J
Int J Pancreatol; 1997 Aug; 22(1):73-5. PubMed ID: 9387028
[No Abstract] [Full Text] [Related]
9. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
[TBL] [Abstract][Full Text] [Related]
10. Immunological factors and risk of infection in plateau phase myeloma.
Hargreaves RM; Lea JR; Griffiths H; Faux JA; Holt JM; Reid C; Bunch C; Lee M; Chapel HM
J Clin Pathol; 1995 Mar; 48(3):260-6. PubMed ID: 7730490
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: current treatment.
Samson D
Postgrad Med J; 1994 Jun; 70(824):404-10. PubMed ID: 7518081
[No Abstract] [Full Text] [Related]
12. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
13. [Value of the determination of beta-2-microglobulin in the monitoring of myeloma. Apropos of 290 determinations].
Kaltwasser P; Sauger F; Le Loet X; Pasquis P; Monconduit M; Deshayes P
Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):359-63. PubMed ID: 6179150
[TBL] [Abstract][Full Text] [Related]
14. [Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].
Bataille R; Grenier J
Presse Med; 1986 Oct; 15(34):1723-5. PubMed ID: 2947132
[TBL] [Abstract][Full Text] [Related]
15. Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases.
Child JA; Kushwaha MR
Hematol Oncol; 1984; 2(4):391-401. PubMed ID: 6396193
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
Cuzick J; De Stavola BL; Cooper EH; Chapman C; MacLennan IC
Br J Haematol; 1990 Aug; 75(4):506-10. PubMed ID: 2119793
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
Cuzick J; Cooper EH; MacLennan IC
Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
